Veracyte, Inc.
NASDAQ:VCYTBiotechnology
+$1.83 today
- Market cap
- $2.06B
- Beta
- 1.98
- P/E (TTM)
- 48.0
- EPS (TTM)
- $1.11
Volume 2.45M
Average 1.05M
VCYT Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Veracyte, Inc.NASDAQ: VCYT
Net Debt · Q2 FY2026 · quarter ended Jun 2026
Net debt remains negative
Q2 FY2026 net debt was -$259.41M, compared with -$168.85M a year earlier.
Context
- Net debt amounted to 17.5% of total assets at the end of Q2 FY2026, up 4.9 pp from a year earlier.
- Net debt grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -53.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (322.92M) USD
- Year-over-year change
- -71.4%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (322.92M) | -71.4% |
| FY2024 | 2024-12-31 | (188.35M) | +7.6% |
| FY2023 | 2023-12-31 | (203.82M) | -46.1% |
| FY2022 | 2022-12-31 | (139.53M) | +9.6% |
| FY2021 | 2021-12-31 | (154.34M) | — |
Net Debt vs competitors
How VCYT compares with its peers on the latest reported figures
- VCYT's Jun 2026 net debt of -$259.41M is the 9th highest of the 10 companies compared; the peer median is $46.04M.
- Its year-over-year change of -53.6% is the 9th highest of 10, against a peer median of +8.8%.
- Net debt amounts to 17.5% of total assets for VCYT, versus a peer median of 22.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $664.59M | -11.0% | +2.8% | 35.2% | |
| Jun 2026 | $302.83M | +17.8% | -3.5% | 22.4% | |
WGSGeneDx Holdings Corp. | Jun 2026 | $107.09M | +166.0% | — | 22.2% |
| Mar 2026 | $87.1M | +32.4% | -11.9% | 12.9% | |
| Mar 2026 | $46.04M | +3.0% | — | 48.6% | |
IMDXInsight Molecular Diagnostics Inc. | Mar 2026 | -$25.13M | +8.8% | — | 62.2% |
| Mar 2026 | -$27.04M | +57.6% | — | 4.9% | |
| Mar 2026 | -$34.81M | -31.0% | — | 10.7% | |
| Jun 2026 | -$259.41M | -53.6% | — | 17.5% | |
BLLNBillionToOne, Inc. | Jun 2026 | -$404.71M | -392.1% | — | 55.5% |
| Peer median (excluding VCYT) | $46.04M | +8.8% | -3.5% | 22.4% | |
Competitors are the stored peer set for VCYT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 173.2M | 154.25M | 216.45M | 239.09M | 362.58M |
| Short-term Investments | 3.96M | 24.61M | 0 | 50.35M | 50.31M |
| Net Receivables | 41.46M | 44.02M | 40.38M | 46.53M | 44.66M |
| Inventory | 11.23M | 14.29M | 16.13M | 21.75M | 20.55M |
| Other Current Assets | (3.96M) | 11.47M | 12.66M | 14.55M | 10.28M |
| Total Current Assets | 243.1M | 248.64M | 285.62M | 372.27M | 488.38M |
| Property, Plant & Equipment (Net) | 31.14M | 30.86M | 30.86M | 71.14M | 58.79M |
| Goodwill | 707.9M | 695.89M | 702.98M | 745.8M | 767.15M |
| Intangible Assets | 202.73M | 174.87M | 88.59M | 102.3M | 89.15M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.95M | 6.17M | 6.85M | 8.53M | 2.55M |
| Total Non-current Assets | 944.72M | 907.79M | 829.29M | 927.77M | 917.64M |
| Total Assets | 1.19B | 1.16B | 1.11B | 1.3B | 1.41B |
| Account Payables | 12.36M | 11.91M | 12.94M | 8.63M | 4.59M |
| Short-term Debt | 1.13M | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 4.65M | 2.61M | 2.01M | 1.67M | 1.16M |
| Other Current Liabilities | 33.71M | 36.88M | 29.19M | 47.6M | 28.79M |
| Total Current Liabilities | 64.15M | 62.61M | 61.24M | 78.63M | 59.94M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 5.59M | 4.53M | 734K | 1.23M | 646K |
| Deferred Revenue (Non-current) | 343K | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 7.13M | 3.43M | 1.3M | 972K | 257K |
| Total Non-current Liabilities | 27.16M | 18.61M | 9.56M | 45.44M | 36.51M |
| Total Liabilities | 91.31M | 81.22M | 70.8M | 124.07M | 96.44M |
| Common Stock | 71K | 72K | 73K | 78K | 79K |
| Retained Earnings | (357.16M) | (393.72M) | (468.12M) | (443.98M) | (377.63M) |
| Accumulated OCI | (15.08M) | (31.35M) | (24.02M) | (36.09M) | (8.21M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.1B | 1.08B | 1.04B | 1.18B | 1.31B |
| Total Debt | 18.85M | 14.72M | 12.63M | 50.74M | 39.65M |
| Net Debt | (154.34M) | (139.53M) | (203.82M) | (188.35M) | (322.92M) |
Veracyte, Inc.
NASDAQ:VCYT
Intrinsic Alpha fair value
Locked
Current Price
$25.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.